Head to head
Teduglutide against Apraglutide
The approved daily GLP-2 analogue for short bowel syndrome against a once-weekly one still in development. For a patient injecting every day, the dosing interval is the point of the comparison, and the trials behind each are not the same size.
Column A
TeduglutideTeduglutide (GLP-2 analogue)
An FDA-approved GLP-2 analogue that promotes intestinal growth in short bowel syndrome, reducing dependence on IV nutrition.
Column B
ApraglutideApraglutide (FE 203799), once-weekly GLP-2 analogue
A once-weekly GLP-2 analogue for short bowel syndrome, where teduglutide requires a daily injection. Improved fluid absorption in its phase 2 metabolic balance studies.
Side by side, on the facts we can check
| Attribute | Teduglutide | Apraglutide |
|---|---|---|
| Category | Metabolic | Healing & Recovery |
| FDA status | FDA-approved (Gattex) for short bowel syndrome | Investigational for short bowel syndrome. Not approved at the time of this review. |
| Half-life | ~2 hours | Long-acting, engineered for once-weekly subcutaneous dosing. No specific figure resolved in the sources loaded. |
| Molecular weight | 3,752.1 Da | Modified GLP-2 analogue peptide. No mass asserted; no source loaded states one. |
| Mechanism | Activates GLP-2 receptors in the gut to stimulate growth of the intestinal mucosa and improve nutrient absorption. | A long-acting analogue of glucagon-like peptide-2, a 33-amino-acid proglucagon product released from intestinal L cells. GLP-2 acts on the intestinal epithelium to increase mucosal growth, villus height and crypt depth, slow gastric emptying and transit, and increase intestinal blood flow, which together raise absorptive capacity. Structural modification gives it a half-life long enough for weekly dosing, against teduglutide's daily schedule. |
| Human studies cited | 3 | 2 |
| Legal status, US | FDA-approved, prescription only | Investigational, not approved |
Frequently asked questions
What is the difference between Teduglutide and Apraglutide?
Teduglutide: An FDA-approved GLP-2 analogue that promotes intestinal growth in short bowel syndrome, reducing dependence on IV nutrition. Apraglutide: A once-weekly GLP-2 analogue for short bowel syndrome, where teduglutide requires a daily injection. Improved fluid absorption in its phase 2 metabolic balance studies.
Which has stronger research evidence, Teduglutide or Apraglutide?
This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the Teduglutide profile were human work, against 2 of 2 for Apraglutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Teduglutide and Apraglutide FDA-approved?
Teduglutide: FDA-approved (Gattex) for short bowel syndrome. Apraglutide: Investigational for short bowel syndrome. Not approved at the time of this review..
Related posts
Blog articles that cover Teduglutide or Apraglutide, newest first.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.